Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response

Roberto LatagliataDepartment of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, ItalyCorrespondence[email protected]

Angela RomanoDepartment of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy

Marco ManciniDepartment of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy

Massimo BrecciaDepartment of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy

Ida CarmosinoDepartment of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy

Federico VozellaDepartment of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy

Chiara MontagnaDepartment of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy

Paola VolpicelliDepartment of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy

Federico De AngelisDepartment of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy

Luigi PetrucciDepartment of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy

Alessandra SerraoDepartment of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy

Matteo MolicaDepartment of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy

Adriano SalaroliDepartment of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy

Daniela DiverioDepartment of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy

Giuliana AlimenaDepartment of Cellular Biotechnologies and Hematology, “Sapienza” University of Rome, Rome, Italy

Your download is now in progress and you may close this window